Table 2.
Prevalence of Unlicensed CBD Product Administration to Children With ADHD, ASD, and GAD by Diagnosis and Geographic Region
| Diagnosis | Uses CBD, n (%) | Does Not Use CBD, n (%) |
|---|---|---|
| ADHD, GAD, ASD* | ||
| ADHD only (n = 242) | 61 (25.2) | 181 (74.8) |
| GAD only (n = 61) | 22 (36.1) | 39 (63.9) |
| ASD only (n = 47) | 13 (27.7) | 34 (72.3) |
| At least 2 of the diagnoses (n = 138) | 53 (38.4) | 85 (61.6) |
| All 3 diagnoses (n = 29) | 12 (41.4) | 17 (58.6) |
| Other diagnoses† | ||
| OCD (n = 71) | 36 (50.7) | 35 (49.3) |
| Conduct disorder (n = 24) | 11 (45.8) | 13 (54.2) |
| MDD (n = 73) | 32 (43.8) | 41 (56.2) |
| Geographic region* | ||
| South (n = 211) | 65 (30.8) | 146 (69.2) |
| Northeast (n = 70) | 13 (18.6) | 57 (81.4) |
| Midwest (n = 124) | 36 (29.0) | 88 (71.0) |
| West (n = 83) | 36 (43.4) | 47 (56.6) |
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; CBD, cannabidiol; GAD, generalized anxiety disorder; MDD, major depressive disorder; OCD, obsessive-compulsive disorder
* p < 0.050.
† No statistical analysis performed.